ADMA Biologics to Participate in Upcoming Investor Conferences
September 02 2020 - 7:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that Adam Grossman, President and Chief
Executive Officer, is scheduled to participate in the following
upcoming investor conferences in September:
- H.C. Wainwright 22nd Annual Global Investment Conference on
Monday, September 14, 2020 at 2:30 p.m. ET.
- 2020 Cantor Virtual Global Healthcare Conference on Thursday,
September 17, 2020 at 11:20 a.m. ET.
- Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
on Tuesday, September 22, 2020 at 9:10 a.m. ET.
Webcasts of the live presentations will be
available on the Company’s website at
https://ir.admabiologics.com/events-webcasts and will be archived
for 90 days following the event.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures
and markets three United States Food and Drug Administration (FDA)
approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA Bio Centers subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT: Brian Lenz Executive Vice
President and Chief Financial Officer | 201-478-5552
| www.admabiologics.com
INVESTOR RELATIONS CONTACT:Sam MartinManaging
Director, Argot Partners | 212-600-1902 | sam@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Sep 2023 to Sep 2024